Eric J. Feldman
Weill Medical College of Cornell University and New York Presbyterian Hospital
525 East 68th St
New York
NY 10021
USA
Name/email consistency: high
- First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Feldman, E.J., Lancet, J.E., Kolitz, J.E., Ritchie, E.K., Roboz, G.J., List, A.F., Allen, S.L., Asatiani, E., Mayer, L.D., Swenson, C., Louie, A.C. J. Clin. Oncol. (2011)
- On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Feldman, E.J., Cortes, J., DeAngelo, D.J., Holyoake, T., Simonsson, B., O'Brien, S.G., Reiffers, J., Turner, A.R., Roboz, G.J., Lipton, J.H., Maloisel, F., Colombat, P., Martinelli, G., Nielsen, J.L., Petersdorf, S., Guilhot, F., Barker, J., Kirschmeier, P., Frank, E., Statkevich, P., Zhu, Y., Loechner, S., List, A. Leukemia (2008)
- Farnesyltransferase inhibitors in myelodysplastic syndrome. Feldman, E.J. Curr. Hematol. Malig. Rep (2006)
- Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Feldman, E.J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G.J., Miller, C., Chopra, R., Jurcic, J.C., Brown, R., Ehmann, W.C., Schulman, P., Frankel, S.R., De Angelo, D., Scheinberg, D. J. Clin. Oncol. (2005)
- Monoclonal antibody therapy in acute myeloid leukemia. Feldman, E.J. Curr. Hematol. Rep. (2003)
- The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A., Silver, R.T. Exp. Hematol. (2003)